2022 was another big year for Shockwave and Q4 was no exception! On Twitter, the first Shockwave L6 cases were posted by physicians who participated in its limited release and it was great to see their excitement for our new large-vessel peripheral IVL catheter launching soon in the U.S.! At VIVA ‘22, Dr. Ehrin Armstrong presented the final 1,373 patient cohort data from the Disrupt PAD III Observational Study; this larger patient data set reinforces the predictability of Shockwave IVL and its ability to consistently modify calcium across vessel beds, challenging lesions and complex patients. Additionally, international calcium experts shared their real-world experiences with the safety and efficacy of coronary IVL across different calcium morphologies, including concentric, eccentric and nodular calcium. Check out that and more in the new PulsePoint Newsletter!
Read More
Topics:
Coronary IVL,
Peripheral IVL,
IVL Technology,
Coronary Clinical Data,
Peripheral Conferences,
Peripheral Clinical Data,
SWAV News,
Shockwave C2,
Coronary Conferences,
Shockwave S4,
PulsePoint Newsletter,
Calcium Corner,
Shockwave M5 & Shockwave M5+,
Reimbursement,
Treating Different Ca++ Morphologies,
Female vs. Male Outcomes,
Empower CAD
It was smooth sailing for Shockwave this summer! Thank you to everyone who made Q3 unforgettable; but before we get cozy for the holidays, let’s reflect on the events that made the quarter one to remember. This year’s TCT was particularly momentous, as we announced the first prospective, female-only study of coronary interventions, EMPOWER CAD. We also explored tips and tricks for IVL with guide extension catheter usage with Dr. Stephan Heo and debated different approaches to modifying nodular calcium with an expert panel. Read up on the latest Shockwave IVL peer-written publications and more in the Q3 PulsePoint Newsletter.
Read More
Topics:
Coronary IVL,
Peripheral IVL,
IVL Technology,
Coronary Clinical Data,
Peripheral Conferences,
Peripheral Clinical Data,
SWAV News,
Shockwave C2,
Coronary Conferences,
Shockwave S4,
PulsePoint Newsletter,
Calcium Corner,
Shockwave M5 & Shockwave M5+,
Female vs. Male Outcomes,
Empower CAD
In a few weeks, we are headed to a city known for its sunshine and southern hospitality, Atlanta, Georgia, where SCAI 2022 is taking place this year. At the conference, leading calcium experts will share the 1-year results from the Randomized Disrupt PAD III Trial and 1-year sex specific outcomes with Coronary IVL.
Read More
Topics:
Coronary IVL,
Peripheral IVL,
IVL Technology,
Peripheral Conferences,
SWAV News,
Shockwave C2,
Coronary Conferences,
Shockwave S4,
Shockwave M5 & Shockwave M5+
Acute recoil is a phenomenon in small arteries, such as those below-the-knee (BTK), when there is a significant reduction in luminal gain within just a few minutes after balloon angioplasty. Since the goal of BTK angioplasty is to maximize distal flow in order to heal wounds, recoil is a significant problem. As a result, reducing the incidence of acute recoil should be an important goal in improving BTK treatment.
Read More
Topics:
Peripheral IVL,
Peripheral Clinical Data,
Shockwave S4
VIVA is always one of the best peripheral meetings every year, and we’re especially excited this year because we’ve got something new to show you: Shockwave S4.
Read More
Topics:
Peripheral Conferences,
Shockwave S4
The experience with Intravascular Lithotripsy in a wide variety of peripheral lesions continues to grow.
Critical limb ischemia (CLI) is the most advanced form of peripheral artery disease and often involves stenoses in calcified below-the-knee (BTK) arteries.
Read More
Topics:
Shockwave S4